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Therapeutic drug monitoring is a powerful strategy known to improve the
clinical outcomes and to optimise the healthcare resources in the treatment
of autoimmune diseases. Currently, most of the methods commercially
available for the quantification of infliximab (IFX) are ELISA-based, with a
turnaround time of approximately 8 h, and delaying the target dosage
adjustment to the following infusion.
Aim
To validate the first point-of-care IFX quantification device available in the
market – the Quantum Blue Infliximab assay (Buhlmann, Schonenbuch,
Switzerland) – by comparing it with two well-established methods.
Methods
The three methods were used to assay the IFX concentration of spiked
samples and of the serum of 299 inflammatory bowel diseases (IBD)
patients undergoing IFX therapy.
Results
The point-of-care assay had an average IFX recovery of 92%, being the
most precise among the tested methods. The Intraclass Correlation Coeffi-
cients of the point-of-care IFX assay vs. the two ELISA-based established
methods were 0.889 and 0.939. Moreover, the accuracy of the point-of-care
IFX compared with each of the two reference methods was 77% and 83%,
and the kappa statistics revealed a substantial agreement (0.648 and 0.738).
Conclusions
The Quantum Blue IFX assay can successfully replace the commonly used
ELISA-based IFX quantification kits. This point-of-care IFX assay is able to deli-
ver the results within 15 min makes it ideal for an immediate target concentra-
tion adjusted dosing. Moreover, it is a user-friendly desktop device that does not
require specific laboratory facilities or highly specialised personnel.
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INTRODUCTION
Infliximab (IFX), the first anti-tumour necrosis factor
alpha (TNFa) to be approved for the treatment of
inflammatory bowel disorders, is a chimeric monoclonal
IgG1 composed by a murine variable region (25%) and a
constant human region (75%).1–3 Upon binding to TNF,
IFX elicits a number of mechanisms that reduce and
control the inflammatory response, including the down-
regulation of local and systemic pro-inflammatory
cytokines, the induction of T-cell apoptosis, and the
reduction in leucocytes and lymphocytes migration
towards the inflammatory focus.2, 3
However, and in spite of the efficacy demonstrated by
IFX in the treatment of several autoimmune inflamma-
tory disorders, certain patients do not respond or have a
limited response to IFX therapy. In the specific case of
inflammatory bowel disorders (IBD), 10–30% of the
patients do not respond to IFX induction (primary non-
responders), whereas an annual rate of 13% of the initial
responders tend to stop due to loss of response.4–6 It is
nowadays increasingly acknowledged that low trough
levels of serum IFX can explain the lack of response to
therapy. Although the cut-off levels are still debatable, it
has been clearly established in the literature that IFX
nonresponders have significantly lower serum trough
levels of the drug.4, 7 Moreover, several published studies
demonstrate a clear positive correlation between IFX
serum levels and rates of endoscopic improvement and
remission, whereas undetectable IFX levels place patients
at an increased risk of colectomy.8–11 Overall, IFX serum
trough levels between 3 and 7 lg/mL are commonly
accepted by physicians and researchers as being the opti-
mal therapeutic window during the maintenance
phase.6, 12–14
The interindividual variation in IFX serum levels in
IBD patients is known to be the result of multiple fac-
tors: whereas the immunogenicity of the drug and the
consequent formation of antibodies to IFX is widely
studied, other factors, such as body mass index, albumin
serum concentration, gender, smoking and disease activ-
ity/duration are known to impact the pharmacokinetics
and pharmacodynamics of IFX, therefore, having a role
in the drug availability on the patients’ serum.4, 15, 16
Despite the underlying reasons for this variability, moni-
toring of serum IFX concentrations and of the formation
of anti-drug antibodies during therapy (Therapeutic
Drug Monitoring, TDM) is a powerful tool to aid physi-
cians in the therapeutic decision-making process in the
case of loss or of suboptimal response.12–14, 17 Moreover,
TDM may also support IFX de-escalation in case of
supratherapeutic serum concentrations, enhancing the
cost-effectiveness of the therapeutic process and avoiding
unnecessary side effects.12–14, 18
As TDM relies on an efficient and accurate quantifica-
tion of serum IFX levels and anti-drug antibodies, several
methods have been developed, validated and made com-
mercially available for use in hospitals and reference lab-
oratories. Some of them are able to measure both IFX
and antibodies to IFX, whereas others are specific for
one of these quantifications. Most of the available meth-
ods rely on an Enzyme-Linked Immunosorbent Assay
(ELISA) technique, whereas alternative ones, based on,
for instance, immunoaffinity magnetic purification cou-
pled with high-temperature reversed-phase liquid chro-
matography, fluid-phase radioimmunoassays (RIA),
reporter gene assays and liquid chromatography linked
with mass spectrometry are becoming increasingly
acknowledged.19–25
This study aimed to evaluate the performance of the
first point-of-care IFX-quantification assay available in
the market by comparing it to two established ELISA
methods, using spiked samples and a large and wide-
ranged set of clinical samples.
MATERIAL AND METHODS
Samples and patients
Spiked samples of known IFX concentrations (0.5, 1, 1.5,
3, 5, 7, 10, 15, 20, 30 and 40 lg/mL) were generated by
diluting the appropriate amount of exogenous IFX
(Schering Plough, New Jersey, USA) into a pool of
serum from control donors (after signing consent
forms). Serum samples for IFX quantification were
prospectively and consecutively obtained from a multi-
centric cohort of IBD out-patients in the maintenance
phase of IFX therapy during routine consultations and
immediately before the IFX infusion. The Ethics Com-
mittees of all involved institutions approved this study,
and all patients were required to sign a written informed
consent prior to their participation. Blood samples were
collected, centrifuged and serum samples were kept at
80 °C until being processed.
IFX-quantification assays
The assay being tested was the Quantum Blue Inflix-
imab: Quantitative Lateral Flow Assay (Buhlmann,
Sch€onenbuch, Switzerland) – hereafter referred to as
point-of-care QB – and the sample quantification was car-
ried out strictly respecting the manufacturers’ instructions
in an open-label fashion. A chip card, provided with each
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test kit, supplied the point-of-care QB reader with the test
information and calibration curve for each specific car-
tridge lot. Briefly, serum samples were diluted 1:20 and a
70 lL aliquot was loaded into the port of the test car-
tridge. After a 15 min reaction, the cartridge was read and
the results were shown on the point-of-care QB reader
display. According to the manufacturer, this kit has the
following analytical characteristics: the limit of detection
is 0.15 lg/mL, and the lower and upper limits of quantifi-
cation are 0.4 lg/mL and 20 lg/mL respectively.
The point-of-care QB was compared with two well-
established ELISA-based IFX-quantification tests: the
Level Infliximab M2920 kit (Sanquin, Amsterdam, the
Netherlands) – hereafter referred to as Sanquin – and an
‘in house’ validated procedure. The Sanquin was per-
formed according to the manufacturers’ instructions,
whereas the ‘in house’ procedure has been carried out as
described elsewhere.26–29 Briefly, regarding the ‘in house’
procedure, serum samples were diluted (1:100) and
added to a plate pre-coated with TNFa (Peprotech,
Rocky Hill, NJ, USA). After 60 min of incubation and
an appropriate number of washes, a horseradish peroxi-
dase (HRP)-labelled goat anti-human Fc fragment anti-
body (MP Biomedicals, Solon, OH, USA) was added and
the plate was incubated for 60 min. Afterwards, tetram-
ethylbenzidine (Millipore, MA, USA) substrate was
added, and the reaction was stopped 3 min later with
2M H2SO4. Finally, the samples’ absorbance was read at
450/540 nm, and the IFX was quantified by interpolating
the absorbance values in a standard curve built with
known concentrations of exogenous IFX (Schering
Plough, NJ, USA). According to the manufacturer, the
Sanquin kit has the following analytical characteristics:
the lower and upper limits of quantification are 0.08 lg/
mL (1:200) and 47 lg/mL (1:2000) respectively. For the
‘in house’ procedure, the upper limit of quantification
was calculated as the highest concentration of the stan-
dard curve 9 the sample dilution factor used.
Statistical analyses
Continuous variables were described using the median
and interquartile range (IQR) or the average and the
standard deviation (when appropriate). The level of sta-
tistical significance was set at 0.05. For statistical pur-
poses, the results of all patients’ samples for which the
concentration measured by the point-of-care QB was
below or above the limits of quantification (0.4 lg/mL
and 20 lg/mL, respectively) were considered to be those
same limits. The accuracy and kappa statistics were com-
puted based on a pre-established therapeutic window of
IFX. Statistical Package for Social Sciences (IBM SPSS
Statistics for Windows, Version 20.0. Armonk, NY,
USA) and GraphPad Prism version 6.0 for Windows
(GraphPad Software, La Jolla California USA) were used
for the statistical analysis and plots’ design.
RESULTS
The point-of-care QB assay and the two reference meth-
ods were used to measure the IFX concentrations in
known IFX-spiked samples to compare their intravari-
ability and recovery rates (Figure 1). The point-of-care
QB assay had the smaller intravariability and the better
(i.e. closer to real concentrations) recovery rates. In fact,
the average recovery rate of the point-of-care QB assay
was 92% (ranging from 68% to 108%), compared to
151% (ranging from 57% to 225%) and 114% (ranging
from 79% to 160%) for the ‘in house’ and Sanquin meth-
ods respectively.
Moreover, IFX was quantified in a total of 299 serum
samples using the three different tested assays. These
samples were collected from the same number of IBD
patients, a multicentric cohort with a median (IQR) age
of 34 (24–45) years and composed of 50% males. All
these patients were in the maintenance phase of IFX
therapy. The correlation between the IFX levels obtained
with each of the three assays is shown in Figure 2. All
correlations are significant, with the highest correlation
coefficient being found for the Sanquin and the point-of-
care QB assay (0.952). Considering the correction made
for samples which results were above the limit of detec-
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Figure 1 | IFX quantification of exogenously spiked IFX
samples of known concentrations. The bars indicate the
mean concentration obtained with each assay in the
different concentrations and the error bars refer to the
standard deviation.
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excluded and a new correlation analysis was made
(Table S1). The pattern of correlations and their signifi-
cance are similar to those using the entire set of samples.
Quantitative analysis
The Intraclass Correlation Coefficients (ICC) for the
paired-comparisons of the IFX-quantification assays used
in this study are listed in Table 1. The highest ICC was
found when comparing the Sanquin and point-of-care
QB assays (0.939). Interestingly, the highest mean differ-
ence was also found between these two assays (0.92),
and the 95% IC did not include 0, showing that the con-
centrations measured by the Sanquin kit were consis-
tently higher than those measured by the point-of-care
QB. Moreover, these analyses were repeated excluding all
samples that had a result higher than 20 lg/mL with the
point-of-care QB kit, and the results were similar
(Table S2). The only difference was the highest mean
difference being found for the ‘in house’-QB comparison,
and its 95% CI also excluding 0.
The Bland–Altman plots show a greater dispersion in
the comparison of the ‘in house’ with the point-of-care
QB assay (Figure 3). It should be noticed that this
dispersion is mainly localised in the 10–15 lg/mL range
of concentrations, whereas the dispersion in the compar-
ison of the Sanquin with the point-of-care QB assay
seems to increase gradually with the increase in the mea-
sured concentrations. These analyses were repeated
excluding all samples that had a result higher than
20 lg/mL with the point-of-care QB kit and the results
were similar (Figure S1).
Qualitative analysis
For the qualitative analyses, the results for each method
were stratified according to a commonly accepted IFX
therapeutic window – lower than 3 lg/mL, 3–7 lg/mL
and higher than 7 lg/mL. The agreement, that is, the
percentage of patients that were classified in the same
group using the point-of-care QB and one of the refer-
ence assays – was then analysed (Table 2). The accura-
cies between the point-of-care QB and the ‘in house’ and
Sanquin assays were high (77% and 83% respectively).
The kappa statistic revealed that the point-of-care QB
assay had a substantial agreement with both reference
assays, according to the kappa’s level of agreement
published by Landis and Koch.30
DISCUSSION
This study aimed to evaluate the performance of a new
point-of-care assay to determine serum IFX concentra-
tions that has been recently launched in the market. To
do so, this new test was used to quantify IFX in spiked
samples and in the serum of 299 IBD patients under IFX
maintenance therapy, and the results were compared
with those obtained using two well-established ELISA
methods (the Sanquin and an ‘in house’ assay). The
results were very promising, as the new point-of-care QB
assay revealed an excellent performance when measuring
the spiked samples with known IFX concentrations. In
fact, the point-of-care QB assay performed better than
Figure 2 | Dispersion matrix of the IFX quantification in
the 299 patients’ samples considering the three used
methods (lg/mL). The Spearman correlation
coefficients are the following: 0.919 for the ‘in-house’
method vs. the Sanquin kit (P < 0.001); 0.913 for the
‘in-house’ method vs. the point-of-care Quantum Blue
kit (P < 0.001); and 0.952 for the Sanquin kit vs. the
point-of-care QB kit (P < 0.001).
Table 1 | Intraclass correlation coefficients (ICC) and
differences found upon comparing the different IFX-
quantification assays
ICC Differences








0.939 0.924–0.952 0.92 0.54–1.30
Aliment Pharmacol Ther 2016; 44: 684–692 687
ª 2016 John Wiley & Sons Ltd
Point-of-care infliximab quantification
Figure 3 | Bland–Altman plots
comparing the point-of-care
Quantum Blue with the in
house and Sanquin assays.
Table 2 | Qualitative comparison between the point-of-care Quantum Blue and the reference assays
QB < 3 lg/mL 3 lg/mL < QB > 7 lg/mL QB ≥ 7 lg/mL
Accuracy Kappa (95% CI)n (%) n (%) n (%)
In house <3 lg/mL 100 (75.8) 1 (1.4) 0 (0.0) 77% 0.648 (0.577–0.719)
3 lg/mL ≤ in house > 7 lg/mL 31 (23.5) 48 (66.7) 14 (14.7)
In house ≥ 7 lg/mL 1 (0.8) 23 (31.9) 81 (85.3)
Sanquin < 3 lg/mL 119 (90.2) 4 (5.6) 0 (0.0) 83% 0.738 (0.673–0.803)
3 lg/mL ≤ sanquin > 7 lg/mL 12 (9.1) 48 (66.7) 14 (14.7)
Sanquin ≥ 7 lg/mL 1 (0.8) 20 (27.8) 81 (85.3)
688 Aliment Pharmacol Ther 2016; 44: 684–692
ª 2016 John Wiley & Sons Ltd
J. Afonso et al.
the two reference methods both in terms of intravariabil-
ity and recovery rates. Regarding the quantitative analy-
sis of the results obtained from the patients’ serum, both
reference methods had a significant correlation with the
point-of-care QB, and the ICCs were consistently high
(0.889 and 0.939). Interestingly, although the Sanquin
assay was the closest to the point-of-care QB, it also had
a bias of 0.92, revealing that the former kit measures
consistently higher values than the latter. This result
finds support at the concentrations obtained from the
spiked samples, in which in all but the 40 lg/mL sample
higher values were obtained when using Sanquin instead
of point-of-care QB. Moreover, this IFX overestimation
of the Sanquin assay has been noticed elsewhere, where
the average percentage of IFX recovery for this kit was
shown to be 139%.21 The differences found upon com-
paring the different methods, as well as those between
measured and nominal values, are noteworthy. However,
one should keep in mind that these differences are inher-
ent to the nature of IFX itself and that of the ELISA
method. In fact, IFX is a monoclonal antibody, and
therefore, affinity variation is an issue in ELISA assays.31
Moreover, being a solid-phase capture assay, ELISA tech-
niques may present some problems in the anti-TNF-anti-
body ligation. Steenholdt et al. have recently published a
revision in which the technical biases of measuring IFX
are well described and documented.32
Interestingly, the Bland–Altman plots of the patient’s
measurements locate the differences between the point-
of-care QB and the other two assays in different ranges
of concentrations. In fact, and concerning the ‘in house’
assay, most differences that fall out of the 95% CI are
located in the 10–15 lg/mL range of concentrations,
whereas concerning the Sanquin assay the differences
increase as the IFX concentrations raise.
The qualitative analysis of the results is more impor-
tant in this context, as the placement of a patient within
a certain range of IFX concentrations will be reflected in
the clinical decisions made if TDM is applied. In this
regard, the samples were stratified according to one pos-
sible IFX therapeutic window for the maintenance phase
of IFX treatment: lower than 3 lg/mL, within the range
of 3–7 lg/mL, and higher than 7 lg/mL. The groups
formed by the point-of-care QB and each of the refer-
ence assays based on this particular criteria were rather
similar: indeed, the kappa statistics indicate a substantial
agreement between them. From a clinical point of view,
the quantification of IFX coupled with the assessment of
the anti-drug antibodies is a powerful tool to guide the
physicians’ therapeutic decisions: using this particular
IFX therapeutic window, a patient with IFX levels lower
than 3 lg/mL should escalate the dosage (either increas-
ing the amount of IFX in the infusions or decreasing the
interval between them) or switch to a different intra- or
interclass drug – depending on the presence and concen-
tration of antibodies to IFX; a patient with IFX levels
within the range of 3–7 lg/mL does not need dosage
adaptation; and a patient with IFX levels higher than
7 lg/mL can safely de-escalate the dosage.6, 12–14
According to our results, the clinical decision based on
the IFX quantification only (but prone to further adjust-
ments should the concentration of antibodies to IFX be
known) would be of a similar nature in 77% of the
patients – using the point-of-care QB instead of the ‘in
house’ assay – or in 83% of the patients – using the
point-of-care QB instead of the Sanquin assay. Con-
versely, 24% and 10% of the patients considered to have
an IFX concentration below the optimal therapeutic win-
dow when evaluated by the point-of-care QB were actu-
ally within or above this window when their serum was
assayed with the ‘in house’ or Sanquin methods respec-
tively. Moreover, approximately 33% of the patients
considered within the therapeutic window by the
point-of-care QB assay were actually above or below it
according to the tests used as reference, whereas 15% of
the patients placed by the QB point-of-care test above
the therapeutic window were considered to be within
that window when assayed by the Sanquin and ‘in house’
methods. Although these percentages may seem note-
worthy, it is important to highlight that the decisions
made following a TDM approach must be integrated in
the patients’ clinical context. As so, it is likely that con-
sidering the presence of symptomatology and other dis-
ease markers would dilute these differences, particularly
in the cases where patients are placed in different groups
using two different assays, but the measured IFX concen-
trations are actually borderline the therapeutic window.
Moreover, the 3–7 lg/mL therapeutic window used in
our study is a commonly used reference, but different
thresholds have been established for different methods
by different authors. Our results are only indicative of an
overall qualitative agreement during IFX maintenance
therapy, but the specific percentages would obviously
vary should a different therapeutic interval be used. Fur-
ther studies are needed to integrate the clinical status
and disease progression of the patients with the perfor-
mance of the point-of-care QB assay in a TDM context,
as well as to define specific IFX cut-offs that should be
applied with this method in the different therapeutic
phases.
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The clinical advantage of using a point-of-care assay
for the monitoring of IFX (and other variables) in the
IBD patients is rather evident: the turnaround time of
the point-of-care QB assay is 15 min, compared to the
approximately 8 hours taken by a common ELISA-based
kit. This allows the physician to optimise the IFX treat-
ment immediately when using the point-of-care QB, as
opposed to optimise the treatment in the following infu-
sion (usually 6–8 weeks later) when using one of the
commercially available ELISA-based kits. The benefits of
optimising the IFX therapy in IBD and other inflamma-
tory diseases’ treatment are amply acknowledged in the
literature. In fact, adjusting the IFX doses (either escalat-
ing or de-escalating) and the infusion intervals has been
proved to be a clinically powerful tool and a cost-effec-
tive strategy.12–14, 16–18, 33 For those reasons, a serious
effort of the medical and research community has been
recently applied to the development of novel point-of-
care assays concerning the IBD patients monitoring.34–37
However, most of these tests are focused on disease
activity. To the best of our knowledge, there are only a
couple of pilot studies describing other lateral flow based
assays for the on-site monitoring of serum IFX
levels.38, 39 The Quantum Blue Infliximab: Quantitative
Lateral Flow Assay from Buhlmann assay is the first test
already developed and launched in the market for this
purpose, and our analysis is the first extensive evaluation
of its performance by comparing it with other two
already established methods.
Another important advantage of this point-of-care QB
assay is its user friendliness: this desktop device may be
operated by any nurse, physician or researcher, as
opposed to the current commercially available ELISA-
based kits and other IFX-quantification methods, which
require highly trained personnel and specific laboratory
facilities. Moreover, the ELISA-based assays should be
run in batches for the sake of cost-effectiveness, which,
depending on the dimension of the IBD population
being followed in each care centre, may represent a fur-
ther delay. The point-of-care QB test, on the other hand,
is designed to be individually used for each patient sam-
ple. As a limitation, whereas ELISA-based methods are
usually able to measure antibodies to IFX in addition to
IFX itself, the point-of-care QB assay, for the time being,
measures only the IFX concentration.
As the main aim of this study was to assess whether
the point-of-care QB could effortlessly replace the time-
consuming and difficult to apply ELISA-based kits, we
focused our efforts in the comparison between the differ-
ent assays, and we have not taken into consideration the
analytical performance characteristics of the point-of-
care QB kit. These have, however, been thoroughly
analysed by the manufacturers, have been reported else-
where,40 and are clearly indicated in the instructions
booklet that accompanies the kit. In this respect, it is
worth noticing that the point-of-care QB limits of quan-
tification are 0.4–20 lg/mL. The lower and upper limits
of detection may hold a disadvantage when compared to
the ELISA-based kits or other IFX-quantification meth-
ods. Although the point-of-care QB assay was shown to
perform rather well in concentrations above its upper
limit after adjusting the dilution factor (Figure 1), we
were unable to do so in the patients’ samples and we
have chosen to strictly respect the indications available
in the kit’s booklet. As so, and for statistical purposes,
we have considered all patients’ samples that were below
the limit of detection to have an IFX concentration of
0.4 lg/mL, and all patients’ samples that were above the
limit of detection to have an IFX concentration of
20 lg/mL. This strategy had an obvious impact in the
quantitative analyses of the patients’ samples, although
the overall results remained very satisfactory. Moreover,
the quantitative analyses were repeated excluding all val-
ues that had a result higher than 20 lg/mL with the
point-of-care QB assay, and the results were shown to be
similar (Tables S1, S2 and Figure S1). Finally, and as the
limits of detection are rather far apart the IFX therapeu-
tic window (3–7 lg/mL), they should have no clinical
impact in the physician assessment and decision-making
process.
This study involved spiked samples and a large num-
ber of serum samples, which were obtained from a mul-
ticentric and heterogeneous cohort and are therefore a
faithful representation of the reality. Notwithstanding,
there were a couple of limitations that should be noticed
and taken into account: the IFX quantification was
always made by the same researcher, which hampers the
assessment of the interassay variability; moreover, the
presence of antibodies to IFX and other compounds that
may differentially interfere with the IFX quantification in
each kit was unaccounted for.
On the basis of this study, we may conclude that the
point-of-care Quantum Blue is a reliable alternative to
the time-consuming ELISAs, allowing the fast and accu-
rate assessment of IFX levels, which in turn contributes
towards a proactive and cost-effective therapeutic
managing of IBD patients. In the era of the personalised
medicine, the fast implementation of tailored therapeutic
solutions is important for the patients’ quality of life and
the healthcare resources optimisation.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Bland–Altman plots excluding samples
>20 lg/mL according to the point-of-care QB assay.
Table S1. Spearman correlation coefficients excluding
samples >20 lg/mL according to the point-of-care QB
assay.
Table S2. Intraclass Correlation Coefficients and dif-
ferences found upon comparing the different IFX-quanti-
fication assays excluding samples >20 lg/mL (according
to the point-of-care QB assay).
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